Company Overview of Regen BioPharma Inc.
Regen BioPharma Inc. develops medicine platforms for the rapid commercialization of stem cell therapies. The company was founded in 2012 and is based in the United States. Regen BioPharma Inc. operates as a subsidiary of Bio-Matrix Scientific Group, Inc.
4700 Spring Street
La Mesa, CA 91942
Founded in 2012
Key Executives for Regen BioPharma Inc.
Chairman of the Board of Directors
Compensation as of Fiscal Year 2014.
Regen BioPharma Inc. Key Developments
Regen BioPharma Provides Update on dCellVax Breast Cancer Immunotherapy
Aug 1 14
Regen BioPharma Inc. reported on progress in development of dCellVax, a "therapeutic cancer vaccine" which stimulates the immune system of patients to selectively kill tumors. The dCellVax therapeutic product is based on extracting blood from patients, growing a specialized type of immune cell from the blood called the "dendritic cell" and then subsequently genetically modifying the dendritic cell to become resistant to cancer's immune suppressive activity. It is known that cancer modifies the immune system by producing proteins which result in immune suppression. One such protein which cancer stimulates is an enzyme, indolamine 2.3 deoxygenase (IDO), which cancer turns on in dendritic cells. While dendritic cells are usually immune stimulators, dendritic cells found in cancer patients suppress the immune system as a result of expressing IDO. By administering dendritic cells that are silenced for IDO, it has been demonstrated that substantially enhanced antitumor responses may be stimulated. Although Regen BioPharma and Dr. Wei-Ping Min have previously published in the area of gene silencing, all work has been performed in animal studies. These are the first experiments in which human cells were utilized in a manner similar to which will be filed with the FDA.
Regen BioPharma Provides Update on HemaXellerate I IND for Treatment of Drug Resistant Aplastic Anemia
May 12 14
Regen BioPharma Inc. announced an update on its IND # 15376 for use of HemaXellerate I(TM) in treatment of patients with drug refractory aplastic anemia. On March 6, 2014, Regen submitted a protocol modification, additional details on manufacturing, and new data to the FDA regarding therapeutic effects of HemaXellerate I(TM) in animal models of diseases similar to aplastic anemia in humans, as well as additional safety data. The company reported that the FDA accepted the clinical protocol and the product manufacturing information provided, however, clarification on animal safety studies was requested. On May 9, 2014 the company updated its IND with changes requested by the FDA and submitted them for review.
Regen BioPharma Inc. Enters into Preclinical Trials Agreement for Hemaxellerate I Covering Aplastic Anemia
Sep 26 13
Bio-Matrix Scientific Group Inc. announced its subsidiary Regen BioPharma Inc. signed an agreement with Dr. Wei-Ping Min covering experiments requested by the FDA in support of clearance for the company's IND #15376 for use of HemaXellerate I in the treatment of drug refractory aplastic anemia. The company filed an Investigational New Drug (IND) application for HemaXellerate I in February 2013 seeking permission from the FDA to initiate a ten patient clinical trial. The FDA reviewed the Company's IND application and had a series of questions, which the company responded to on June 7th. The first series of comments were related to the manufacturing of HemaXellerate I and were successfully addressed. Subsequently the FDA responded with a second series of comments relating to cellular responses in mouse models of aplastic anemia.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 1, 2013
Most Searched Private Companies
Sponsored Financial Commentaries